发明申请
US20150313927A1 AN EDIBLE COMPOSITION COMPRISING RESVERATROL AND FLAVONOID MONOGLUCOSIDE
有权
包含RESVERATROL和FLAVONOID MONOGLUCOSIDE的食用组合物
- 专利标题: AN EDIBLE COMPOSITION COMPRISING RESVERATROL AND FLAVONOID MONOGLUCOSIDE
- 专利标题(中): 包含RESVERATROL和FLAVONOID MONOGLUCOSIDE的食用组合物
-
申请号: US14647751申请日: 2013-11-27
-
公开(公告)号: US20150313927A1公开(公告)日: 2015-11-05
- 发明人: Mark John Berry , Mark Ian Fowler , Alan David Heath
- 申请人: Mark John Berry , Mark Ian Fowler , Alan David Heath
- 申请人地址: US NJ Englewood Cliffs
- 专利权人: Conopco, Inc., d/b/a UNILEVER
- 当前专利权人: Conopco, Inc., d/b/a UNILEVER
- 当前专利权人地址: US NJ Englewood Cliffs
- 优先权: EP12195842.5 20121206
- 国际申请: PCT/EP2013/074833 WO 20131127
- 主分类号: A61K31/7048
- IPC分类号: A61K31/7048 ; A23L1/30 ; A23L2/52 ; A61K31/05
摘要:
Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. Repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. In a first aspect of the invention, an edible composition is provided, in the form of a single serving of one or more unit dosages, wherein the edible composition comprises 20-2000, preferably 30-1000, most preferably 40-500 mg a 3,5-dihydroxy-trans-stilbene and 10-2000, preferably 20-1000, most preferably 40-500 mg flavonoid mono-glucoside or dihydrochalcone monoglucoside.
公开/授权文献
信息查询